Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. PMID: 31876900 Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Sev...
The most frequent adverse events were seen in patients taking the higher dose of medication compared to those taking placebo in the dupilumab group (>1%). These included injection site reactions; eye and eyelid inflammation, including redness, swelling, and itching; and cold sores in the mouth o...
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. PMID: 31876900 Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Sev...
Atopic dermatitis (AD) is a representative chronic inflammatory systemic disease1, and various treatments have been developed depending on the stage2,3. From classical systemic immunosuppressants to newly developed biologics and small molecules that inhibit various cytokines that contribute to the immune ...
ATOPIC dermatitisDUPILUMABECZEMACHILD patientsThirteen patients had a subsequent 4-month follow-up visit reporting mean eosinophilia of 0.08 and mean total IgE of 7.11, 10 patients had EASI of 0, and three patients had EASI of 2. The mean time from treatment initiation to dose decalage was ...
Solution for Injection 300 mg/2mL 200 mg/1.14mL Available as a single-dose prefilled syringe Dosage Considerations – Should be Given as Follows: Moderate-to-Severe Atopic Dermatitis Indicated whendermatitisis not adequately controlled with topical prescription therapies or when those therapies are not...
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet Lond Engl. 2016;387(10013):40–52. Article CAS Google Scholar Simpson EL, Gadkari A, Worm M,...
Inflammation of your blood vessels.Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by DUPIXENT....
These children included 262 (92%) who were being treated with dupilumab for atopic dermatitis, 16 (6%) who were being treated for asthma and four (1%) who were being treated for eosinophilic esophagitis. The cohort included 281 children who received the first dose of the MMR vaccine. Although...
high-dose glucocorticosteroids (≥ 2 mg/kg or a total dosage of ≥ 20 mg/day for ≥ 2 weeks or < 2 mg/kg/day if chronically administered) or biological agents (anti-TNFα, rituximab, anti-IL-6, and anti-CD11a) [29]. However, EULAR also advises carefully weighing ...